Yesterday, The Estée Lauder Cos. announced it collabrate with Serpin Pharma, a company renowned for its two decades of research into anti-inflammatory technologies for broadening its innovation efforts by turning to the pharmaceutical and biotechnology sectors for new ingredients. Estee Lauder is set to explore groundbreaking new possibilities for its products. Serpin Pharma has developed Serine Protease Inhibitors, a class of proteins that reduce inflammation, and Lauder will be delving into how these proteins, along with other proprietary technologies, can be applied to the beauty industry.
This partnership aligns with Lauder’s “Beauty Reimagined” strategy, which was unveiled by the company’s newly appointed CEO, Stéphane de La Faverie, alongside the brand’s latest financial results. The initiative reflects Lauder’s commitment to driving innovation and accelerating its product development through a newly restructured organization designed to bring cutting-edge solutions to market more efficiently.
Lauder is actively evaluating the potential applications of Serpin Pharma’s technology across its diverse brand portfolio, which spans a range of price points and product categories, from high-end lines like La Mer and Estée Lauder to more accessible offerings such as Aveda and The Ordinary. According to Carl Haney, Executive Vice President of Global Innovation, Research and Development at Lauder, this collaboration will propel the company’s innovation agenda, exploring new biological pathways and cutting-edge biotech ingredients to address visible skin irritation and sensitivity.
Cohava Gelber, founder and CEO of Serpin Pharma, emphasized the company’s approach, rooted in biomimicry, which taps into the body’s natural mechanisms for resolving inflammation.
